<DOC>
	<DOCNO>NCT01858519</DOCNO>
	<brief_summary>This point prevalence study conduct entirely United States ( US ) establish prevalence antibody hepatitis E virus ( HEV ) select porcine virus cystic fibrosis ( CF ) patient receive pancreatic enzyme replacement therapy ( PERT ) pancreatic insufficiency compare match ( age region residence ) control patient chronic medical condition unexposed PERT .</brief_summary>
	<brief_title>Prevalence Antibodies Selected Porcine Viruses Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy</brief_title>
	<detailed_description>This multicenter , non-interventional point-prevalence study conduct US determine seroprevalence antibody select porcine virus pancreatic enzyme replacement therapy-exposed CF patient unexposed control group chronic medical condition match age geographic region residence . Data collection include demographic medical history , pancreatic enzyme replacement therapy , transfusion history , history potential exposure pig virus . If patient meet requirement study provide study specific informed consent/assent , single blood sample obtain part plan standard-of-care blood collection . This harmonized protocol reflect equal sponsorship register Sponsor , AbbVie , also Collaborators , Aptalis Pharma Janssen Research &amp; Development , LLC .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>All Patients ( PERTexposed unexposed control ) must meet following criterion : Have blood draw plan part standard care follow enrollment study ; Provide inform consent/assent . Patients PERTExposed Group must meet following criterion : Have diagnose CF ; Have receive PERT minimum 6 month . Patients Unexposed Control Group must meet following criterion : Be medical management chronic disease ; Never receive PERT product ; Match enrol PERTexposed patient base age regionofresidence . Have blood draw plan perform within 180 day match PERTexposed patient blood draw . Has porcine heart valve , porcinederived graft , exposure porcine derive insulin . This exclusion apply previous porcinederived heparin exposure . ; Refuses blood collection ; Has condition , opinion investigator , would make participation best interest ( e.g. , compromise wellbeing ) patient could prevent , limit , confound protocolspecified assessment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pancreatic enzyme replacement therapy</keyword>
	<keyword>antibody</keyword>
	<keyword>porcine virus</keyword>
	<keyword>epidemiology</keyword>
	<keyword>prospective</keyword>
</DOC>